Athira Pharma, Inc. (ATHA)
ATHA moved a median of 0.00% 30 minutes after news, and -0.40% by the close. How ATHA actually reacts to news — the realized, point-in-time move the market made, measured across 245 labeled events over the last three years with zero look-ahead.
ATHA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 180 |
| 30-min | 0.00% | 49% | 181 |
| 60-min | -0.46% | 39% | 181 |
| to close | -0.40% | 48% | 181 |
| Middle 50% of ATHA reactions | -1.33% to +1.32% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 245 |
Half of all Athira Pharma, Inc. news events land between -1.33% and +1.32% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ATHA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ATHA's baseline. Nothing else.
Recent ATHA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K LeonaBio, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form ARS LeonaBio, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | — | |
| Form DEF 14A LeonaBio, Inc. For: Jun 22 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form DEFA14A LeonaBio, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | — | — | |
| Form 10-Q LeonaBio, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K LeonaBio, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form EFFECT LeonaBio, Inc. | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Form S-8 LeonaBio, Inc. | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Form 10-K LeonaBio, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | — | |
| Form 8-K/A LeonaBio, Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form S-1/A LeonaBio, Inc. | SEC filing · Form S-1 | SEC EDGAR | — | — | |
| Form 8-K LeonaBio, Inc. For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K LeonaBio, Inc. For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form DEFR14A LeonaBio, Inc. | SEC filing · Form DEFR14A | SEC EDGAR | — | — | |
| Form DEF 14A LeonaBio, Inc. For: Mar 18 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form PRE 14A LeonaBio, Inc. For: Mar 18 | SEC filing · Form PRE | SEC EDGAR | — | — | |
| Form S-3 LeonaBio, Inc. | SEC filing · Form S-3 | SEC EDGAR | — | — | |
| Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” | Press release | GlobeNewswire | +0.03% | -7.53% | |
| Form 8-K LeonaBio, Inc. For: Jan 07 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million | Press release | GlobeNewswire | +6.22% | -7.05% | |
| Form 8-K Athira Pharma, Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +6.22% | -7.05% | |
| Form 8-K/A Athira Pharma, Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | +6.22% | -7.05% | |
| Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | -1.52% | -2.53% | |
| Form 10-Q Athira Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.52% | -2.53% | |
| Form 8-K Athira Pharma, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -1.52% | -2.53% | |
| Form 8-K Athira Pharma, Inc. For: Oct 02 | SEC filing · Form 8-K | SEC EDGAR | — | -0.48% | |
| Athira Pharma Announces Reverse Stock Split | Press release | GlobeNewswire | +5.38% | +6.43% | |
| Form 8-K Athira Pharma, Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +5.38% | +6.43% | |
| Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 | Press release | GlobeNewswire | +0.00% | +2.08% | |
| Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +1.77% | +1.82% | |
| Form 10-Q Athira Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.77% | +1.82% | |
| Form 8-K Athira Pharma, Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +1.77% | +1.82% | |
| Form 8-K Athira Pharma, Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -1.86% | +7.96% | |
| Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit | Press release | GlobeNewswire | +2.31% | -0.46% | |
| Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates | Press release | GlobeNewswire | +0.04% | -5.92% | |
| Form 10-Q Athira Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.04% | -5.92% | |
| Form 8-K Athira Pharma, Inc. For: May 09 | SEC filing · Form 8-K | SEC EDGAR | +0.04% | -5.92% | |
| Form 8-K Athira Pharma, Inc. For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | +1.14% | |
| Form ARS Athira Pharma, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.39% | -5.58% | |
| Form DEF 14A Athira Pharma, Inc. For: May 29 | SEC filing · Form DEF | SEC EDGAR | +1.39% | -5.58% | |
| Form DEFA14A Athira Pharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.39% | -5.58% | |
| Form PRE 14A Athira Pharma, Inc. For: May 29 | SEC filing · Form PRE | SEC EDGAR | -11.53% | -0.48% | |
| Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates | Press release | GlobeNewswire | -0.02% | +0.15% | |
| Form 10-K Athira Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.02% | +0.15% | |
| Form 8-K Athira Pharma, Inc. For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -0.02% | +0.15% | |
| Form S-8 Athira Pharma, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.02% | +0.15% | |
| Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND | Press release | GlobeNewswire | -1.34% | -0.84% | |
| Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | Press release | GlobeNewswire | -4.29% | -7.71% | |
| Form 10-Q Athira Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -4.29% | -7.71% | |
| Form 8-K Athira Pharma, Inc. For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | -4.29% | -7.71% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ATHA section they belong to.
Where else ATHA is measured.
ATHA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Athira Pharma, Inc.'s median reaction calculated?
Every labeled ATHA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 245 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of ATHA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ATHA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.